Methylphenidate transdermal - Nutriband
Alternative Names: Defent™ Methylphenidate transdermal systemLatest Information Update: 15 Apr 2024
At a glance
- Originator Nutriband
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder; Narcolepsy
Most Recent Events
- 08 Apr 2024 United States Patent and Trademark Office (USPTO) grants Prioritized Examination (Track One) to the US patent application for 'Abuse and misuse deterrent transdermal systems'
- 25 Mar 2024 Preclinical trials in Attention-deficit hyperactivity disorder in USA (Transdermal)
- 20 Sep 2023 Nutriband has patent protection for Transdermal Abuse Deterrent Technology in US